A Phase 2 Study to Evaluate Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec (Q203) in Covid-19 Patients

NCT04847583 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor's Decision

Conditions

COVID-19 Virus Infection

Interventions

DRUG: Telacebec
DRUG: COVID-19 Standard of care

Sponsor

Qurient Co., Ltd.